Company intelligence
pixlbio
pixl x bio: from cells to pixels to predictions
About pixlbio
pixlbio is redefining predictive biology. Formed from the merger of DefiniGEN (UK) and Phenaros (Sweden), we combine iPSC-derived human models with high-throughput imaging and AI-powered phenomics to uncover subtle cellular insights that animal models can’t. Our platform captures millions of images and profiles hundreds of millions of cells each week, turning complex biology into predictive clarity for drug discovery and safety. What we offer: - iPSC-derived hepatocytes, stellates & intestinal organoids - Validated disease models (MASLD/MASH, A1ATD, Wilson’s) - AI-driven phenomics - Proprietary automation and SaaS access Trusted by 11 of the top 20 pharma companies, leading biotechs, and research institutions worldwide. We’re ISO 9001:2015 certified and expanding into cardiac and renal models — building the next generation of predictive biology. ✨ Every cell tells a story. Every pixel holds a clue.
Verified activity
Signals from pixlbio
4 published signals
Presence & Recognition
pixlbio's CSO Jordi Carreras Puigvert is speaking at 10:45am on how the approach combining pixHep, iPSC-derived hepatocytes, and pixCellPaint improves decision making in pre-clinical liver safety.
Reported by pixlbio
Presence & Recognition
pixlbio's Precision, Prediction & the 3Rs has sold out with Labcorp and Novo Nordisk hosting.
Reported by pixlbio
Products & Services
pixlbio offers pixCRISPR, a gene-editing and differentiation service for disease models including LDLR, SERPINA1, ATP7B, OTC, ASS1, ABCB11, PAH, and custom targets.
Reported by pixlbio
Presence & Recognition
pixlbio is attending the Precision, Prediction & the 3Rs event on 8 September in Måløv, Denmark hosted by Novo Nordisk, organised by Labcorp.
Reported by pixlbio